| Systematic (IUPAC) name | |
|---|---|
| (RS)-4-(ethyl[1-(4-methoxyphenyl)propan-2-yl]amino)butyl 3,4-dimethoxybenzoate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | POM (UK) |
| Routes | Oral |
| Identifiers | |
| CAS number | 2753-45-9 |
| ATC code | A03AA04 |
| PubChem | CID 4031 |
| ChemSpider | 3891 |
| UNII | 7F80CC3NNV |
| KEGG | D04868 |
| ChEMBL | CHEMBL282121 |
| Chemical data | |
| Formula | C25H35NO5 |
| Mol. mass | 429,6[g/mol] |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Mebeverine is a musculotropic antispasmodic drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965. It is manufactured and marketed as Colofac, Duspatal and Duspatalin by Solvay Pharmaceuticals.
Mebeverine is presented in the United Kingdom as a (135 mg) tablet. Other strengths: 100 mg tablet and 200 mg capsule.
|
Contents
|
Mebeverine is an antimuscarinic. Mebeverine belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, mebeverine has dual mode of action which normalizes the small bowel motility.
Spastic functional disturbances of the colon:
Since 1978, 21 cases of severe adverse reactions to mebeverine were reported in the Netherlands.[1] Most reactions consisted of urticaria or maculopapular rash, sometimes accompanied by fever, polyarthritis, thrombopenia or angioedema.
Very rarely, people taking this medicine may develop allergic reactions.[2]
|
||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)